Medy-Tox Inc.
Financials
Valuation Metrics
Medy-Tox Inc.'s Market Cap is ₩5613B. At end of 2025 it was ₩8817B. Ranked #423 of 2,436 in KR market (top 17%), #143 of 1,649 on KOSDAQ (top 9%), #49 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 21%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 561.25B KRW | KR#423/2,436 Sec#49/234 |
| Revenue | 244.02B KRW | KR#918/2,436 Sec#49/234 |
| Net Income | 20.19B KRW | KR#647/2,436 Sec#45/234 |
| Total Assets | 564.78B KRW | KR#694/2,436 Sec#40/234 |
| Net Assets | 379.71B KRW | KR#595/2,436 Sec#39/234 |
| Employees | 776 | KR#324/2,436 Sec#28/234 |
| Value | ||
| P/E | 27.79x | KR#1,229/2,436 Sec#72/234 |
| P/B | 1.48x | KR#1,781/2,436 Sec#128/234 |
| PEG | 0.20x | KR#530/2,436 Sec#29/234 |
| P/S | 2.30x | KR#1,895/2,436 Sec#110/234 |
| EV/EBITDA | 34.07x | KR#1,233/2,436 Sec#85/234 |
| FCF Yield | 8.15% | KR#689/2,436 Sec#32/234 |
| Profitability | ||
| ROE | 5.32% | KR#958/2,436 Sec#71/234 |
| ROA | 3.58% | KR#861/2,436 Sec#76/234 |
| Op. Margin | 7.75% | KR#650/2,436 Sec#58/234 |
| Revenue Growth | -5.11% | KR#1,705/2,436 Sec#158/234 |
| Earnings Growth | 135.66% | KR#340/2,436 Sec#23/234 |
| Financial Health | ||
| Debt Ratio | 148.74% | KR#1,170/2,436 Sec#134/234 |
| Total Debt | 125.12B KRW | KR#638/2,436 Sec#35/234 |
| FCF | 45.75B KRW | KR#322/2,436 Sec#18/234 |
| Cash | 42.48B KRW | KR#834/2,436 Sec#53/234 |
| Current Ratio | 1.01x | KR#1,807/2,436 Sec#181/234 |
| Net Debt/EBITDA | 4.37x | KR#1,048/2,436 Sec#79/234 |
| Dividend | ||
| Div. Yield | 1.67% | KR#996/2,436 Sec#55/234 |
| Div. Growth | 9.09% | KR#604/2,436 Sec#33/234 |
| Performance | ||
| 1Y Return | -46.15% | KR#1,991/2,436 Sec#183/234 |
| 1M Return | -2.78% | KR#1,193/2,436 Sec#115/234 |
| From 52W High | -49.44% | KR#1,165/2,436 Sec#102/234 |
| 1Y MDD | -59.18% | KR#1,361/2,436 Sec#109/234 |
| Trading | ||
| Volume | 27,951 shares | KR#1,686/2,436 Sec#168/234 |
| Foreign Own. | 15.89% | KR#294/2,436 Sec#17/234 |
| Per Share | ||
| EPS | 2,660 KRW | KR#310/2,436 Sec#20/234 |
| BPS | 53,877 KRW | KR#225/2,436 Sec#15/234 |
Company Info
Established in 2000 and listed on KOSDAQ in 2009, Meditox engages in the research, development, manufacturing, and sale of Botulinum Toxin Type A and biopharmaceuticals. The company's main products are Meditoxin Inj., Coretox, and Innotox, developed with proprietary original technology. With the KFDA product approval for Neurtoxin in 2023, it is expanding into domestic and international markets while diversifying its portfolio with hyaluronic acid fillers, liquid toxin formulations for US entry, and genetically recombinant toxins. Meditox is headquartered in Cheongwon-gun, Chungcheongbuk-do.